FILINGS
| GSK 0001131399 | |||
|---|---|---|---|
| Filing Date | Form Type | Description | Document |
| 2025-01-16 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-01-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-01-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-01-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-01-13 | 6-K | GSK ENTERS AGREEMENT TO ACQUIRE IDRX, INC. | View Document |
| 2025-01-10 | 6-K | SHINGRIX FULLY LIQUID ACCEPTED FOR US FDA REVIEW | View Document |
| 2025-01-07 | 6-K | GSK ADC GETS FDA BREAKTHROUGH THERAPY DESIGNATION | View Document |
| 2025-01-03 | 6-K | GSK'S NUCALA APPROVED IN CHINA FOR USE IN CRSWNP | View Document |
| 2025-01-02 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-12-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-12-20 | 6-K | BLOCK LISTING APPLICATION | View Document |
| 2024-12-20 | 6-K | HEADLINE RESULTS FROM PHASE III FIRST TRIAL | View Document |
| 2024-12-16 | 6-K | JEMPERLI RECEIVES US FDA BREAKTHROUGH DESIGNATION | View Document |
| 2024-12-16 | 6-K | EMA GRANTS PRIME DESIGNATION FOR GSK 227 | View Document |
| 2024-12-16 | 6-K | JEMPERLI RECEIVES POSITIVE CHMP OPINION | View Document |
| 2024-12-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-12-09 | 6-K | OVERALL SURVIVAL DATA PRESENTED FOR BLENREP | View Document |
| 2024-12-09 | 6-K | BLENREP COMBINATION CHINA FILING ACCEPTANCE | View Document |
| 2024-12-09 | 6-K | NUCALA COPD SUBMISSION ACCEPTED BY US FDA | View Document |
| 2024-12-05 | 6-K | ZHIFEI CHINA COLLABORATION REVISED AND EXTENDED | View Document |
| 2024-12-02 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-12-02 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-11-27 | 6-K | GSK LIQUID MENINGITIS VACCINE AUTHORISED IN EU | View Document |
| 2024-11-25 | 6-K | BLENREP COMBINATIONS ACCEPTED FOR US FDA REVIEW | View Document |
| 2024-11-22 | 6-K | JAPAN APPROVES FIRST RSV VACCINE FOR ADULTS 50-59 | View Document |
| 2024-11-19 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-11-19 | 6-K | GLISTEN TRIAL OF LINERIXIBAT MEETS ENDPOINT | View Document |
| 2024-11-15 | SC 13D/A | AMENDMENT TO THE SCHEDULE 13D | View Document |
| 2024-11-14 | 6-K | GSK ANNOUNCES OVERALL SURVIVAL RESULTS FOR BLENREP | View Document |
| 2024-11-13 | 6-K | BLOCK LISTING INTERIM REVIEW | View Document |
| 2024-11-12 | SC 13G/A | AMENDMENT TO FORM SC 13G | View Document |
| 2024-11-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-11-12 | 6-K | GSK PUBLISHES PROVISIONAL 2025 DIVIDEND DATES | View Document |
| 2024-11-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-10-30 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-10-30 | 6-K | 3RD QUARTER RESULTS | View Document |
| 2024-10-24 | 6-K | NEW POSITIVE AREXVY DATA IN YOUNGER ADULTS AT RISK | View Document |
| 2024-10-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-10-16 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-10-16 | 6-K | FDA ACCEPTS NEW DRUG APPLICATION FOR GEPOTIDACIN | View Document |
| 2024-10-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-10-15 | 6-K | POSITIVE RESULTS OF ANCHOR TRIALS OF DEPEMOKIMAB | View Document |
| 2024-10-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-10-10 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-10-09 | 6-K | ZANTAC (RANITIDINE) LITIGATION SETTLEMENTS | View Document |
| 2024-10-08 | 6-K | POSITIVE EFFICACY DATA OF AREXVY OVER 3 SEASONS | View Document |
| 2024-10-01 | 4 | WVE - CHANGE IN BENEFICIAL OWNERSHIP | View Document |
| 2024-10-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-09-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-09-24 | 6-K | POSITIVE EU OPINION FOR GSK LIQUID MENVEO VACCINE | View Document |
| 2024-09-18 | 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 2024-09-17 | 6-K | JAPAN FILING ACCEPTANCE: BLENREP MULTIPLE MYELOMA | View Document |
| 2024-09-13 | 6-K | CHINA BREAKTHROUGH THERAPY DESIGNATION FOR BLENREP | View Document |
| 2024-09-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-09-12 | 6-K | POSITIVE MRNA FLU VACCINE PHASE II HEADLINE DATA | View Document |
| 2024-09-11 | 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 2024-09-11 | 6-K | CHANGE OF REGISTERED OFFICE | View Document |
| 2024-09-11 | 6-K | UPDATE ON PHASE I/II THERAPEUTIC HSV VACCINE TRIAL | View Document |
| 2024-09-09 | 6-K | DEPEMOKIMAB LATE-BREAKING DATA PRESENTED AT ERS | View Document |
| 2024-09-06 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-09-06 | 6-K | POSITIVE PHASE III RESULTS FOR NUCALA IN COPD | View Document |
| 2024-09-03 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-08-29 | 6-K | EMA APPROVAL ON AREXVY FOR 50-59 AT RISK | View Document |
| 2024-08-28 | 6-K | NUCALA APPROVED IN JAPAN FOR USE IN CRSWNP | View Document |
| 2024-08-28 | 6-K | SENKU DESIGNATION FOR BEPIROVIRSEN IN JAPAN | View Document |
| 2024-08-28 | 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 2024-08-21 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-08-20 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-08-20 | 6-K | B7-H3 ADC US FDA BREAKTHROUGH THERAPY DESIGNATION | View Document |
| 2024-08-16 | 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 2024-08-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-08-06 | 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 2024-08-02 | 6-K | FDA EXPANDS JEMPERLI APPROVAL | View Document |
| 2024-08-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-07-31 | 6-K | 2ND QUARTER RESULTS | View Document |
| 2024-07-29 | 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 2024-07-29 | 6-K | CHMP POSITIVE OPINION ON AREXVY FOR 50-59 AT RISK | View Document |
| 2024-07-19 | 6-K | BLENREP EMA FILING ACCEPTANCE | View Document |
| 2024-07-18 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-07-16 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-07-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-07-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-07-03 | 6-K | GSK AND CUREVAC COLLABORATION RESTRUCTURED | View Document |
| 2024-07-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-06-28 | 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 2024-06-24 | 6-K | EMA VALIDATES JEMPERLI MARKETING AUTHORISATION | View Document |
| 2024-06-24 | 6-K | OMJJARA APPROVED IN JAPAN FOR MYELOFIBROSIS | View Document |
| 2024-06-21 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-06-18 | 11-K | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE | View Document |
| 2024-06-18 | 11-K | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE | View Document |
| 2024-06-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-06-11 | 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 2024-06-10 | 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 2024-06-10 | 6-K | FDA APPROVES AREXVY FOR ADULTS 50-59 AT RISK | View Document |
| 2024-06-03 | 25-NSE | View Document | |
| 2024-06-03 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-06-03 | 6-K | UNPRECEDENTED RESULTS IN JEMPERLI TRIAL CONTINUE | View Document |
| 2024-06-03 | 6-K | ASCO POSITIVE BLENREP DREAMM-8 TRIAL RESULTS | View Document |
| 2024-06-03 | 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 2024-05-31 | SD | SPECIALIZED DISCLOSURE REPORT | View Document |
Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.
